Dexpramipexole Treatment for Elevated Eosinophil and Basophil Levels

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for conditions associated with elevated levels of eosinophils and/or basophils, such as eosinophilic asthma, are limited by significant side effects, refractoriness to corticosteroids, and immunological reactions from biologic therapies, necessitating a safe and effective small molecule alternative.

Innovation Solution

Administering dexpramipexole or its pharmaceutically acceptable salts to reduce eosinophil and/or basophil levels, optionally with adjunctive agents, to treat conditions characterized by elevated granulocytes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If corticosteroids are used to treat eosinophilic asthma, then eosinophil levels are reduced, but significant side effects occur and refractoriness develops

Engineering Contradiction:

Improveeosinophil levelsVSAvoidside effects and refractoriness

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameter from corticosteroids to dexpramipexole, a small molecule with a different mechanism of action. This parameter change allows reduction of eosinophil levels while avoiding the harmful side effects and refractoriness associated with corticosteroid therapy

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a small molecule (dexpramipexole) instead of complex biologic therapies or long-term corticosteroid regimens. The small molecule acts as a temporary, replaceable therapeutic agent that can be administered without causing cumulative harm or permanent side effects

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Quantity of substance

If biologic therapies are used to treat eosinophilic asthma, then eosinophil levels are reduced, but immunological reactions occur

Engineering Contradiction:

Improveeosinophil levelsVSAvoidimmunological reactions

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent uses dexpramipexole as an intermediary substance that indirectly reduces eosinophil levels through a non-immunological mechanism. Rather than directly targeting eosinophils or their receptors (which would trigger immunological reactions), the small molecule acts as a mediator that modulates the inflammatory pathway upstream, avoiding direct immune system activation

Inventive Principle:

Principle #24Intermediary (Mediator)

3Quantity of substance

If existing therapies are used to treat elevated eosinophils and basophils, then granulocyte levels are reduced, but significant side effects and immunological reactions occur

Engineering Contradiction:

Improvegranulocyte levelsVSAvoidside effects and immunological reactions

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent employs a small molecule (dexpramipexole) as a temporary, non-cumulative therapeutic agent that can be administered repeatedly without causing permanent harm. This small molecule approach replaces complex biologics and long-term corticosteroid therapy, providing a safe, disposable therapeutic solution that reduces granulocyte levels without significant side effects

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentEP3838271B1Treating elevated levels of eosinophils and/or basophils

Publication Date: 2025.09.03 ARETEIA THERAPEUTICS INC

Figure 1
Figure 2A~2B
Figure 3A~3B

AI summary

Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.